Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agrippal S1 2010-2011 influenza vaccine safety and immunogenicity study in adults and elderly subjects
2010-018583-17Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of influenza vaccine, inactivated, surface antigen in influenza (2 arms), sponsored by Novartis. Primary endpoints: Immunogenicity to each influenza vaccine antigen at Day 21 in non-elderly adults, Immunogenicity to each influenza vaccine antigen at Day 21 in elderly subjects and 3 more. Started Apr 2010; status: completed.
02
Drugs
influenza vaccine, inactivated, surface antigen
03
Conditions
influenza
Beyond the preview
Go deeper on 2010-018583-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018583-17.